What is dihydroergotamine mesylate?
Dihydroergotamine mesylate (often shortened to DHE) is a prescription medicine used to treat certain types of severe headache episodes, especially migraine attacks, and sometimes related conditions involving abnormal blood vessel tone. It is an ergot-derived drug that acts on serotonin and other receptors, which helps reduce migraine-related blood vessel and pain signaling.
What is it used for?
Dihydroergotamine mesylate is used to treat acute migraine attacks (to stop the attack) and is also used for specific other headache syndromes when a clinician determines an ergot-type therapy is appropriate. Because product labeling and indications can vary by country and formulation, the exact approved uses depend on the specific brand and dosage form.
How is it typically taken (injection vs other forms)?
Common routes include injection or other clinician-directed administration methods, depending on the available formulation. How it’s used (dose, timing from headache onset, and number of doses) depends on the prescribing information for that specific product and the patient’s medical history.
How does it work?
Dihydroergotamine acts on receptors involved in migraine biology, including serotonin receptors. This receptor activity can help reduce the cascade that drives migraine pain and symptoms.
Who should not take it?
Ergot-derived drugs can be unsafe for people with certain cardiovascular or vascular conditions. Dihydroergotamine mesylate may be contraindicated or require special caution in people with:
- Certain forms of coronary artery disease, uncontrolled hypertension, or serious cardiovascular disease
- Peripheral vascular disease
- Specific drug-drug interactions (notably with medicines that affect serotonin receptors or blood vessel tone)
A clinician or pharmacist should review the patient’s full medication list to avoid dangerous interactions.
What drug interactions are most important?
Interactions are a major concern with ergot medicines. In particular, taking dihydroergotamine with other migraine vasoconstrictors can increase risk. Clinicians typically avoid combining it with:
- Other ergot-containing medicines
- Some migraine-specific “triptan” drugs taken close together
- Certain strong CYP3A4 inhibitors (because they can raise dihydroergotamine levels)
Because interaction rules depend on timing and the exact medications, patients should follow individualized guidance from their prescriber.
What side effects do people report?
Common side effects can include nausea and vomiting, dizziness, and tingling or discomfort. Serious complications are possible if blood flow to tissues is affected too strongly (rare but important). Patients are usually instructed to seek urgent care for symptoms such as severe chest pain, signs of poor circulation (for example, cold/pale fingers or toes), or severe allergic reactions.
How fast does it work?
Dihydroergotamine is intended for acute relief, so it’s usually used early in the attack as directed by the product labeling and clinician plan. Time-to-effect varies by route and individual factors.
Is it safe in pregnancy or breastfeeding?
Ergot medicines are generally avoided in pregnancy due to risks associated with ergot derivatives. Breastfeeding recommendations depend on product labeling and clinician advice.
Does it have generics or branded versions?
Dihydroergotamine mesylate is available in multiple brands and may have generic equivalents depending on the country. Formulation differences (for example, injection preparations) affect dosing instructions and safety considerations.
What should a patient ask their doctor or pharmacist?
Patients typically want clear answers on:
- Which product/formulation they are using and the exact dosing schedule
- Whether they can use it with their current migraine medicines
- What symptoms would require stopping the medicine and seeking emergency care
- Whether it’s appropriate given their cardiovascular history and risk factors
Sources
No sources were provided in the prompt, so I can’t cite specific labeling, clinical trial data, or regulatory documents here. If you share the country/brand name or the exact context (migraine acute treatment vs another indication), I can tailor the answer to that specific approved use and formulation.